Xenoport, Inc. (NASDAQ:XNPT) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.
Xenoport, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share decreased to $-0.51 in the quarter versus EPS of $-0.22 in the year-earlier quarter.
Revenue: Decreased 79.77% to $2.1 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Xenoport, Inc. reported adjusted EPS loss of $0.51 per share. By that measure, the company beat the mean analyst estimate of $-0.53. It beat the average revenue estimate of $1.74 million.
Quoting Management: Ronald W. Barrett, Ph.D., chief executive officer of XenoPort, stated, “Working with GSK to correct its prior product stockout and then our relaunch of Horizant were key accomplishments for the quarter, and I am happy that Horizant is now broadly available to adult patients with moderate-to-severe primary restless legs syndrome and postherpetic neuralgia (PHN). We hope that our focused commercial plan will establish a successful template for commercializing Horizant. We believe that there is a clear need for a non-dopaminergic treatment for RLS and were gratified to see Horizant included as a first-line treatment in the IRLSSG guidelines for restless legs syndrome. We have also been receiving positive feedback from physicians as we introduce them to the unique attributes of Horizant for the management of PHN.”
Key Stats (on next page)…